TransMedics Group (TMDX) Tops Q2 EPS by 47c ; Offers Guidance

TransMedics Group (NASDAQ: TMDX) reported Q2 EPS of $0.92, $0.47 better than the analyst estimate of $0.45. Revenue for the quarter came in at $157.4 million versus the consensus estimate of $146.74 million.

GUIDANCE:

TransMedics Group sees FY2025 revenue of $585-605 million, versus the consensus of $582.1 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• USA Rare Earth secures $1.55 billion SPV for Serra Verde offtake
• H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)